Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies
Truffle Capital:
1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020
As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.
Here are the latest companies’ breaking news for these three companies:
-
November 19, 2020: Carbios, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios published a major scientific article in Nature, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage.
Link: News/Carbios/First Plastic Bottle from Recycled Textile
Link: News/Carbios/Nature Cover Page
-
December 22, 2020: Abivax, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax ABX464 drug candidate was declared a National Covid-19 Research Priority by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year.
Link: News/Abivax/National Covid-19 Research Priority
-
December 23, 2020: Carmat, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world's most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).
Link: News/Carmat/CE Marking
For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios: www.carbios.fr; Abivax: www.abivax.com and Carmat: www.carmatsa.com).
These companies and their achievements are Truffle Capital's signature as an entrepreneur-investor company: sourcing radical innovations in biotechnology and medical devices from around the world to build leading companies in France and support them towards advanced development stages.
Philippe Pouletty, M.D. co-founder and CEO of Truffle Capital, mentions: “We are proud of these three French companies that would not have existed without Truffle. Contributing to saving lives or protecting our planet, thanks to exceptional scientific research and technologies and to international management teams, fosters the emergence of future World leaders in France, while generating a very good return on investment for Truffle Capital’s funds. We intend to amplify our efforts with our new BioMedTech and Medeor funds, to benefit patients around the world and our investors.”
|
2020 Stock Performance Ranking of Euronext Paris listed BioMedTech Companies, with a Market Capitalization between 200 million and 2 billion euros on 01/01/2020 |
|
Ranking |
Company |
2020 Stock Performance (%) |
Market Capitalization
|
|
1 |
Carbios |
318% |
443 |
|
2 |
AB Sciences |
276% |
752 |
|
3 |
Inventiva |
219% |
572 |
|
4 |
Valneva |
202% |
826 |
|
5 |
Gensight Biologics |
187% |
304 |
|
6 |
Cellectis |
56% |
1098 |
|
7 |
Abivax |
53% |
497 |
|
8 |
Carmat |
47% |
379 |
|
9 |
Innate Pharma |
-42% |
291 |
|
10 |
DBV Technologies |
-78% |
545 |
|
Index |
2020 Performance |
|
CAC 40 |
-7% |
|
Next Biotech |
-6% |
Sources: Price per share variation (%) from 12/31/2019 to 12/31/2020; market capitalization on 01/22/2021. Companies in the diagnostics sector or with market capitalizations less than 200 million euros or over 2 billion euros as of January 1, 2020 were excluded. This ranking was established based on Euronext data.
2. New BioMedTech Companies created by Truffle Capital in Major Healthcare Sectors
Truffle continues to create and support future BioMedTech leaders aiming to treat life threatening diseases. Truffle Early-Stage BioMedTech Funds, which closed at the end of 2019, have already enabled the financing of 8 BioMedTech companies built on promising radical innovations.
- Affluent Medical (Aix en Provence) is developing four minimally invasive medical devices to treat cardiac, vascular and urologic diseases, which are already at an advanced clinical development stage;
- Artedrone (Paris) is aiming to design revolutionary autonomous microrobots allowing interventional radiologists to treat or prevent cerebrovascular accidents without using catheters;
- Bariatek (Paris) is developing a minimally invasive medical device to treat obesity;
- Caranx Medical (Nice) is developing autonomous surgical robots, for vascular and abdominal surgery;
- Diaccurate (Paris) is developing novel anti-cancer and anti-viral drugs based on breakthrough immuno-oncology mechanisms;
- HoliStick Medical (Paris) is developing a medical device to close pathological holes between the right and left heart (PFO) in order to prevent strokes;
- PKMed (Lyon), is developing biocompatible 3D implants to enable local drug delivery or to promote the genesis of functional tissues and organs following cell therapy;
- Skinosive (Marseille) is developing bioadhesive technologies to increase the effectiveness and safety of UV filters and other dermato-cosmetic compounds.
3. MEDEOR, Truffle New Late-Stage BioMedTech Fund, expects a first closing before summer
Truffle new MEDEOR Fund aims to complement Truffle's BioMedTech financing tools for BioMedTech companies, from inception to commercial stages. It has a clear industrial objective: invest at least €600 million in future BioMedTech world leaders developing advanced-stage medical devices (pre-commercial or commercial stage, for 70%) or innovative drugs (phase II & III clinical studies, for 30%). MEDEOR will always be lead investor and major proactive shareholder and board member, to build in France technological leaders that will revolutionize surgery and medicine. French institutional investors and French government granted MEDEOR the “Tibi” label, a French government initiative to encourage LP’s to invest in the best funds.
Thanks to MEDEOR, Truffle Capital intends to continue to lead French BioTech and MedTech companies towards commercial and international medical success.
4. Truffle : a High Performance business model launched twenty years ago
Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital's mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.
2020 was marked by the launch of new innovative projects in its two areas of expertise (BioMedTech and FinTech/InsurTech) and by very significant advances in the field of Biotechnology and Medical Devices.
******
For more information: www.truffle.com — Twitter: @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005496/en/
Contact information
Truffle Capital Investor Relations: Maud Lazare – maud@truffle.com
Media Relations Agency – DGM Conseil
Quentin Hua – quentin.hua@dgm-conseil.fr (+ 33 6 28 63 27 29)
Thomas de Climens – thomasdeclimens@dgm-conseil.fr (+33 6 14 50 15 84)
Hugues Schmitt – h.schmitt@dgm-conseil.fr
Olivier Labesse – labesse@dgm-conseil.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UserTesting Welcomes Two New Members to Its Board of Directors4.3.2021 14:00:00 EET | Press release
UserTesting, a leading provider of on-demand human insights, today announced the addition of two new members to the board of directors with the election of Shannon Nash, and Cindy Russo, who will serve as the audit chair. These two women bring a wealth of financial and operational experience as UserTesting continues to expand and diversify the board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005388/en/ UserTesting Welcomes Two New Members to Its Board of Directors (Graphic: Business Wire) Nash brings more than two decades of experience to the board, and is currently the Chief Accounting Officer at Reputation, the global leader in reputation experience management. Previously, Nash held executive finance roles at Insidesource, Cumulus Media Inc. (NASDAQ: CMLS), Aspire Public Schools, and Sunseeker Media. She is also a board member of the Silicon Valley Community Foundation and on the CalCPA Diversity Equity & Inclus
Ibsen Awards: Announcing Ibsen Scholarships 20214.3.2021 14:00:00 EET | Press release
Looking for funding for your performing arts project? The Ibsen Scholarship program offers funding for innovative performing arts projects worldwide. The scholarship program amounts to a total of NOK 2.000.000,- (approx. Euro 205.000 / USD 248.000). The projects must act as incentives for critical discourses on society related matters and be based on one or more of Henrik Ibsen’s plays. Ibsen Scholarships applications will be evaluated by an appointed jury. For further information, statutes and application form see www.ibsenawards.com Deadline for applications is April 30th 2021. The Ibsen Scholarships were initiated by the Norwegian government in 2007 and will be awarded for the 11th time in 2021. Ibsen Scholarships have been awarded 39 projects in 27 countries. See all winners here: http://ibsenawards.com/scholarship/winners/ The winners of the Ibsen Scholarships 2021 will be invited to Ibsen Awards Festival at Teater Ibsen in Skien, Norway in 2022. View source version on businesswir
Samsung Electronics, Mastercard and Samsung Card Sign MoU for Fingerprint Biometric Payment Card4.3.2021 12:13:00 EET | Press release
Samsung Electronics’ System LSI Business, Mastercard, Samsung Card, have signed a memorandum of understanding to develop a biometric card that features a built-in fingerprint scanner to authorize transactions securely at in-store payment terminals. Through this strategic collaboration, the companies aim to provide faster and more secure payment experiences. The biometric authentication capability allows safer interactions with reduced physical contact points by eliminating the need to enter a PIN on a keypad. It also adds an extra layer of security to currently available credit cards by verifying the cardholder’s identity via a unique fingerprint. The biometric cards will adopt a new security chipset from Samsung’s System LSI Business that integrates several key discrete chips, streamlining the overall component design and enabling more efficient development. These cards can be used at any Mastercard chip terminal or point of sale (POS) terminal. “Drawing from our strong security solut
IDEMIA to Participate in the UK Government’s Digital Identity Pilot4.3.2021 11:00:00 EET | Press release
Pursuant to UK government standards, DCS will provide a powerful new way to help verify UK passport holders’ identity, underpinned by security and user experience. It will help prevent fraud, speed up checks and allow people to prove their identity for both face-to-face and online transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005360/en/ (Photo: Business Wire) The DCS was previously only available for use in government transactions, however can now be used by pilot-participating private sector firms to check passport information provided by UK citizens against government held data. With citizen consent, service providers will use IDEMIA’s IDway solution to instantly check people’s passport details match the UK government’s passport office database. The DCS will then respond yes or no to confirm whether or not the passport details are valid. People’s private data are protected at all times. Matt Warman, UK
VicTrack transforms rail and government infrastructure with ADVA FSP 30004.3.2021 11:00:00 EET | Press release
ADVA (FSE: ADV) today announced that VicTrack is building its new Transport and Government Secure Network (TGSN) on the ADVA FSP 3000. The infrastructure enables railway operators to harness next-generation signaling technologies and provides high-speed connectivity for government agencies. Carrying services at speeds up to 100Gbit/s throughout the Australian state of Victoria, the flexible and fully redundant ROADM network also empowers VicTrack to offer highly reliable and cost-efficient wholesale services at 10Gbit/s and 100Gbit/s. What’s more, the FSP 3000 creates a modular network architecture, which is scalable and ready to support future transport innovation. ADVA’s team is also providing a comprehensive range of professional services from network design to ongoing training and support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005026/en/ ADVA’s open networking technology is helping VicTrack deliver mission
Flagship Report From Arthur D. Little Urges Telcos to Accelerate Growth by Embracing New Services and Reconfiguring Network Assets4.3.2021 11:00:00 EET | Press release
Arthur D. Little (ADL) today released a major telecoms report that identifies key strategies to unlock the value of network assets, diversify product offerings, and succeed in a 5G world. Entitled “Time to accelerate growth” and based on a global survey of over 100 C-level executives, it looks at the ways in which telcos can meet the challenge of soaring data-traffic demands while moving beyond traditional connectivity and legacy services. The report identifies three main areas that telcos should concentrate on going forward: Maximizing 5G’s potential. To further enhance customer experience for B2C, telcos and media companies need to form alliances and use 5G as a means to create new and compelling products for consumers – for example, premium bundles that combine content, experience and devices in novel and exciting ways. To provide solutions to B2B customers beyond connectivity, mobile private networks (MPNs) and network slicing offer key opportunities for 5G monetization. To capture
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe4.3.2021 10:57:00 EET | Press release
Galderma today announced a European re-launch of Sculptra ® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra ® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product. Sculptra ® now has the fastest reconstitution protocol of any injectable poly-L-lactic acid (PLLA) available in Europe, representing a significant growth opportunity for Galderma. “Sculptra ® has been my go-to tool for treating skin laxity resulting from aging and collagen loss in my patients’ skin, helping restore a youthful appearance,” said Dr. Christoph Martschin, Dermatologist, Akademikliniken, Department of Dermatology, Stockholm, and a featured s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom